m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT03043
|
[1] | |||
m6A modification
PTEN
PTEN
YTHDC2
 : m6A sites
Indirect
Enhancement
Histone modification
H3K27me3
PRC2
Downstream Gene
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | YTH domain-containing protein 2 (YTHDC2) | READER | |||
| m6A Target | Mutated in multiple advanced cancers 1 (PTEN) | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | Histone modification (HistMod) | ||||
| Epigenetic Regulator | Polycomb Repressive Complex 2 (PRC2) | WRITER | View Details | ||
| Regulated Target | Histone H3 lysine 27 trimethylation (H3K27me3) | View Details | |||
| Crosstalk Relationship | m6A → Histone modification | Enhancement | |||
| Crosstalk Mechanism | m6A modification indirectly regulates histone modification through downstream signaling pathways | ||||
| Crosstalk Summary | We discovered that YTHDC2 inhibition increased the expression of Mutated in multiple advanced cancers 1 (PTEN) while it decreased the expression of the PRC2 component SUZ12 and the levels of the histone modification Histone H3 lysine 27 trimethylation (H3K27me3). | ||||
| Responsed Disease | Skin cancer | ICD-11: 2C3Z | |||
In-vitro Model |
HaCaT | Normal | Homo sapiens | CVCL_0038 | |
| HEK293T | Normal | Homo sapiens | CVCL_0063 | ||